All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

lisdexamfetamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
anorexics	4135	608137-32-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: lisdexamfetamine lisdexamphetamine lisdexamfetamine dimesylate vyvanse lisdexamfetamine mesilate	A dextroamphetamine drug precursor that also functions as a CENTRAL NERVOUS SYSTEM STIMULANT and DOPAMINE UPTAKE INHIBITOR and is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER. Molecular weight: 263.39 Formula: C15H25N3O CLOGP: 0.81 LIPINSKI: 0 HAC: 4 HDO: 3 TPSA: 81.14 ALOGS: -3.48 ROTB: 8 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
30	mg	O

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	0.60 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	17 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.20 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Feb. 23, 2007	FDA	SHIRE DEVELOPMENT
March 26, 2019	PMDA	SHIONOGI & CO., LTD.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Intentional self-injury	884.02	17.13	318	18201	25369	63445134
Product quality issue	763.68	17.13	313	18206	35552	63434951
Intentional overdose	696.97	17.13	367	18152	73785	63396718
Disturbance in attention	395.48	17.13	202	18317	37987	63432516
Product physical issue	393.91	17.13	116	18403	4864	63465639
No adverse event	193.75	17.13	131	18388	41274	63429229
Inappropriate schedule of product administration	180.52	17.13	185	18334	103780	63366723
Feeling abnormal	173.70	17.13	215	18304	148177	63322326
Drug ineffective	151.97	17.13	652	17867	1044113	62426390
Wrong technique in product usage process	148.19	17.13	132	18387	62208	63408295
Suicidal ideation	144.09	17.13	130	18389	62291	63408212
Anxiety	133.00	17.13	232	18287	217309	63253194
Product tampering	118.95	17.13	27	18492	391	63470112
Irritability	110.76	17.13	84	18435	31610	63438893
Product availability issue	108.50	17.13	42	18477	4079	63466424
Therapeutic product effect increased	103.53	17.13	30	18489	1185	63469318
Tic	101.14	17.13	31	18488	1489	63469014
Inability to afford medication	99.50	17.13	34	18485	2313	63468190
Withdrawal syndrome	95.23	17.13	64	18455	19933	63450570
Product dose omission issue	92.37	17.13	208	18311	234105	63236398
Therapeutic product effect variable	90.19	17.13	27	18492	1196	63469307
Depression	81.43	17.13	178	18341	196314	63274189
Mood swings	81.18	17.13	56	18463	18192	63452311
Therapeutic response unexpected	77.46	17.13	55	18464	18704	63451799
Incorrect dose administered	76.71	17.13	91	18428	59877	63410626
Rhesus incompatibility	72.47	17.13	14	18505	86	63470417
Paranoia	72.02	17.13	44	18475	11635	63458868
Therapeutic response shortened	71.30	17.13	44	18475	11844	63458659
Somnolence	67.44	17.13	156	18363	178529	63291974
Anger	66.93	17.13	43	18476	12413	63458090
Feeling jittery	61.67	17.13	42	18477	13361	63457142
Prescribed overdose	59.57	17.13	61	18458	34092	63436411
Adulterated product	59.24	17.13	14	18505	244	63470259
Attention deficit hyperactivity disorder	59.10	17.13	25	18494	3051	63467452
Claustrophobia	56.19	17.13	18	18501	1000	63469503
Acute kidney injury	55.67	17.13	6	18513	263409	63207094
Psychomotor hyperactivity	55.30	17.13	36	18483	10627	63459876
Insomnia	54.61	17.13	162	18357	215090	63255413
Insurance issue	53.65	17.13	29	18490	6092	63464411
Dermatitis atopic	53.31	17.13	34	18485	9690	63460813
Abnormal behaviour	52.11	17.13	46	18473	21380	63449123
Pulse abnormal	51.44	17.13	21	18498	2343	63468160
Contraindicated product administered	51.43	17.13	3	18516	217645	63252858
Therapeutic product effect decreased	50.52	17.13	147	18372	193040	63277463
Amphetamines negative	49.98	17.13	7	18512	0	63470503
Impulsive behaviour	48.41	17.13	18	18501	1565	63468938
Pre-existing condition improved	48.14	17.13	30	18489	8214	63462289
Pneumonia	47.81	17.13	38	18481	456729	63013774
Joint swelling	47.69	17.13	18	18501	327648	63142855
Premature delivery	45.56	17.13	50	18469	30231	63440272
Aggression	44.70	17.13	44	18475	23454	63447049
Systemic lupus erythematosus	43.52	17.13	5	18514	208913	63261590
Somatic symptom disorder	42.55	17.13	19	18500	2641	63467862
Agitation	42.07	17.13	68	18451	59689	63410814
Suspected product quality issue	40.33	17.13	10	18509	215	63470288
Product administration interrupted	39.86	17.13	22	18497	4814	63465689
Unevaluable event	39.66	17.13	61	18458	51325	63419178
Euphoric mood	39.64	17.13	22	18497	4865	63465638
Brain injury	39.54	17.13	25	18494	7018	63463485
Acne	39.52	17.13	41	18478	23252	63447251
Crying	39.45	17.13	41	18478	23302	63447201
Death	39.33	17.13	31	18488	374350	63096153
Illness	38.94	17.13	59	18460	49000	63421503
Heart rate increased	38.53	17.13	85	18434	94153	63376350
Suicide attempt	38.44	17.13	66	18453	60852	63409651
Logorrhoea	37.20	17.13	17	18502	2493	63468010
Memory impairment	37.08	17.13	89	18430	104169	63366334
Pyrexia	36.96	17.13	50	18469	470428	63000075
Anaemia	36.63	17.13	20	18499	293410	63177093
Amphetamines positive	36.32	17.13	9	18510	193	63470310
Rheumatoid arthritis	35.18	17.13	15	18504	253804	63216699
Diarrhoea	34.69	17.13	101	18418	715265	62755238
Mood altered	34.55	17.13	31	18488	14712	63455791
Treatment failure	34.27	17.13	8	18511	199035	63271468
Neurological symptom	33.65	17.13	21	18498	5762	63464741
Hyperhidrosis	33.05	17.13	87	18432	107749	63362754
Total cholesterol/HDL ratio abnormal	32.61	17.13	7	18512	77	63470426
Hunger	32.48	17.13	20	18499	5359	63465144
Arthropathy	32.34	17.13	14	18505	234778	63235725
Drug intolerance	31.85	17.13	26	18493	308635	63161868
General physical health deterioration	31.10	17.13	10	18509	201392	63269111
Palpitations	30.59	17.13	87	18432	112683	63357820
Infusion related reaction	30.25	17.13	17	18502	245504	63224999
Tremor	30.20	17.13	96	18423	132143	63338360
Educational problem	30.10	17.13	9	18510	397	63470106
Mydriasis	29.73	17.13	26	18493	11930	63458573
Serotonin syndrome	29.43	17.13	39	18480	28643	63441860
Wound	29.24	17.13	6	18513	163257	63307246
Glossodynia	29.23	17.13	8	18511	178868	63291635
Mania	28.97	17.13	26	18493	12341	63458162
Performance status decreased	28.32	17.13	16	18503	3662	63466841
Hyperreflexia	28.26	17.13	19	18500	5915	63464588
Amenorrhoea	27.60	17.13	23	18496	9891	63460612
Product taste abnormal	27.53	17.13	13	18506	2054	63468449
Rabbit syndrome	27.41	17.13	8	18511	324	63470179
Depressed mood	27.28	17.13	45	18474	40146	63430357
Stress cardiomyopathy	26.46	17.13	22	18497	9428	63461075
Bruxism	26.24	17.13	15	18504	3510	63466993
Lower respiratory tract infection	25.56	17.13	4	18515	132303	63338200
Disease progression	25.40	17.13	3	18516	122755	63347748
Vision blurred	25.01	17.13	71	18448	91853	63378650
Stress	24.58	17.13	58	18461	67109	63403394
Increased appetite	24.06	17.13	21	18498	9609	63460894
Fall	23.99	17.13	49	18470	392285	63078218
Feeling hot	23.56	17.13	48	18471	50306	63420197
Haemoglobin decreased	22.86	17.13	7	18512	145478	63325025
Drug diversion	22.62	17.13	9	18510	939	63469564
Hypertensive emergency	22.53	17.13	11	18508	1871	63468632
Thrombocytopenia	22.47	17.13	8	18511	151149	63319354
Arthralgia	22.40	17.13	88	18431	569622	62900881
Febrile neutropenia	21.95	17.13	4	18515	118445	63352058
Exposure via skin contact	21.69	17.13	7	18512	398	63470105
Blood pressure increased	21.53	17.13	99	18420	161963	63308540
Pulmonary embolism	21.50	17.13	4	18515	116680	63353823
Negativism	21.49	17.13	7	18512	410	63470093
Atrial fibrillation	21.48	17.13	4	18515	116632	63353871
Change in sustained attention	21.42	17.13	3	18516	0	63470503
Menstruation irregular	21.07	17.13	17	18502	6987	63463516
Sympathomimetic effect	20.95	17.13	5	18514	91	63470412
Foetal chromosome abnormality	20.93	17.13	4	18515	23	63470480
Migraine	20.88	17.13	72	18447	103274	63367229
Urinary tract infection	20.87	17.13	28	18491	264656	63205847
Muscle spasms	20.45	17.13	95	18424	156055	63314448
Drug dependence	20.21	17.13	30	18489	24453	63446050
Nervousness	20.11	17.13	34	18485	30945	63439558
Respiratory failure	19.85	17.13	3	18516	101855	63368648
Apathy	19.64	17.13	18	18501	8776	63461727
Tachyphrenia	19.41	17.13	9	18510	1365	63469138
Hypotension	19.38	17.13	31	18488	272573	63197930
Bipolar disorder	19.17	17.13	17	18502	7943	63462560
Psychotic disorder	19.10	17.13	30	18489	25682	63444821
Hypoaesthesia	18.88	17.13	98	18421	168295	63302208
Hepatic enzyme increased	18.53	17.13	19	18500	202309	63268194
Oedema peripheral	18.27	17.13	17	18502	189494	63281009
Dermatillomania	18.24	17.13	5	18514	161	63470342
Tardive dyskinesia	18.21	17.13	17	18502	8485	63462018
Swelling	18.03	17.13	33	18486	275345	63195158
Platelet count decreased	17.51	17.13	6	18513	116116	63354387
Infection	17.31	17.13	25	18494	229148	63241355
Poor quality product administered	17.21	17.13	11	18508	3145	63467358
Device expulsion	17.18	17.13	34	18485	34888	63435615
Distractibility	17.15	17.13	6	18513	438	63470065

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product quality issue	774.44	25.35	273	12210	16762	34927686
Product physical issue	371.54	25.35	100	12383	2441	34942007
Intentional self-injury	314.46	25.35	134	12349	13637	34930811
Tic	286.82	25.35	78	12405	1980	34942468
Aggression	280.50	25.35	174	12309	38790	34905658
Disturbance in attention	274.93	25.35	149	12334	25796	34918652
Psychomotor hyperactivity	227.46	25.35	96	12387	9526	34934922
Drug ineffective	224.43	25.35	497	11986	456254	34488194
No adverse event	205.51	25.35	118	12365	22809	34921639
Therapeutic product effect decreased	205.07	25.35	137	12346	34606	34909842
Suicidal ideation	186.44	25.35	137	12346	40251	34904197
Irritability	184.49	25.35	113	12370	24577	34919871
Intentional overdose	179.07	25.35	138	12345	43536	34900912
Abnormal behaviour	175.71	25.35	110	12373	24859	34919589
Inappropriate schedule of product administration	172.77	25.35	157	12326	62139	34882309
Therapeutic product effect increased	172.76	25.35	42	12441	671	34943777
Anxiety	171.96	25.35	194	12289	99234	34845214
Wrong technique in product usage process	152.50	25.35	116	12367	35870	34908578
Insomnia	148.59	25.35	184	12299	103723	34840725
Crying	143.56	25.35	60	12423	5802	34938646
Choreoathetosis	128.28	25.35	36	12447	1028	34943420
Disturbance in social behaviour	124.84	25.35	40	12443	1811	34942637
Oppositional defiant disorder	116.13	25.35	29	12454	520	34943928
Bruxism	114.99	25.35	37	12446	1698	34942750
Anger	108.64	25.35	62	12421	11822	34932626
Decreased eye contact	103.97	25.35	26	12457	469	34943979
Prescribed overdose	103.97	25.35	58	12425	10589	34933859
Mood altered	96.33	25.35	52	12431	8900	34935548
Logorrhoea	95.37	25.35	35	12448	2391	34942057
Acute kidney injury	92.14	25.35	4	12479	304984	34639464
Agitation	88.97	25.35	106	12377	57293	34887155
Homicidal ideation	88.37	25.35	34	12449	2648	34941800
Educational problem	86.28	25.35	23	12460	539	34943909
Feeling abnormal	83.90	25.35	108	12375	63127	34881321
Dyskinesia	83.51	25.35	67	12416	22346	34922102
Negativism	82.99	25.35	21	12462	398	34944050
Incorrect dose administered	81.96	25.35	86	12397	40429	34904019
Emotional disorder	81.11	25.35	40	12443	5676	34938772
Pneumonia	80.56	25.35	16	12467	362611	34581837
Therapeutic response shortened	79.63	25.35	43	12440	7361	34937087
Affect lability	77.94	25.35	34	12449	3649	34940799
Decreased appetite	77.29	25.35	178	12305	166214	34778234
Impulsive behaviour	76.96	25.35	29	12454	2133	34942315
Dystonia	76.78	25.35	48	12435	10797	34933651
Product administered to patient of inappropriate age	71.66	25.35	31	12452	3260	34941188
Anaemia	70.61	25.35	3	12480	233332	34711116
Depressed mood	70.37	25.35	57	12426	19260	34925188
Depression	67.73	25.35	123	12360	96975	34847473
Death	67.56	25.35	29	12454	398020	34546428
Therapeutic product effect variable	63.02	25.35	26	12457	2430	34942018
Trismus	62.63	25.35	26	12457	2469	34941979
Inability to afford medication	60.73	25.35	22	12461	1448	34943000
Trichotillomania	60.52	25.35	12	12471	68	34944380
Attention deficit hyperactivity disorder	58.66	25.35	25	12458	2534	34941914
Product tampering	58.24	25.35	11	12472	46	34944402
Speech disorder	56.40	25.35	57	12426	25629	34918819
Nervousness	56.35	25.35	42	12441	12564	34931884
Sleep disorder	54.88	25.35	62	12421	31626	34912822
Feeling jittery	53.80	25.35	27	12456	3976	34940472
Paranoia	49.07	25.35	38	12445	12030	34932418
Sepsis	47.65	25.35	3	12480	166558	34777890
Breech presentation	46.52	25.35	11	12472	155	34944293
Coordination abnormal	44.67	25.35	30	12453	7614	34936834
Insurance issue	43.71	25.35	19	12464	2020	34942428
Product availability issue	41.82	25.35	18	12465	1869	34942579
Adverse event	41.63	25.35	42	12441	18835	34925613
Oculogyric crisis	41.41	25.35	17	12466	1569	34942879
Product dose omission issue	40.77	25.35	114	12369	119597	34824851
Dermatillomania	39.14	25.35	8	12475	54	34944394
Jaundice neonatal	37.10	25.35	15	12468	1331	34943117
Tardive dyskinesia	36.93	25.35	24	12459	5766	34938682
Foetal distress syndrome	36.43	25.35	14	12469	1086	34943362
Pyrexia	35.59	25.35	40	12443	332973	34611475
Autism spectrum disorder	35.37	25.35	17	12466	2279	34942169
Neutropenia	34.53	25.35	7	12476	156771	34787677
Mania	34.49	25.35	28	12455	9483	34934965
Headache	34.23	25.35	152	12331	200483	34743965
Amphetamines positive	33.71	25.35	9	12474	212	34944236
Hyperkinesia	33.16	25.35	15	12468	1753	34942695
Renal failure	32.87	25.35	4	12479	130553	34813895
Dyspnoea	32.44	25.35	53	12430	376729	34567719
Suspected product tampering	32.34	25.35	5	12478	3	34944445
Product use issue	31.88	25.35	70	12413	63146	34881302
Psychotic disorder	31.18	25.35	41	12442	24411	34920037
Febrile neutropenia	30.36	25.35	6	12477	136843	34807605
Streptococcal infection	30.26	25.35	20	12463	4941	34939507
Change in sustained attention	29.92	25.35	5	12478	8	34944440
Haemoglobin decreased	29.68	25.35	4	12479	120768	34823680
Suicidal behaviour	29.03	25.35	13	12470	1484	34942964
Diarrhoea	28.98	25.35	60	12423	389852	34554596
Rhesus incompatibility	28.92	25.35	6	12477	44	34944404
Thinking abnormal	28.66	25.35	21	12462	6116	34938332
Polydipsia psychogenic	28.66	25.35	7	12476	114	34944334
Obsessive-compulsive disorder	28.18	25.35	20	12463	5544	34938904
Drug withdrawal syndrome neonatal	28.11	25.35	17	12466	3602	34940846
Asthenia	27.79	25.35	28	12455	245223	34699225
Hunger	27.79	25.35	13	12470	1641	34942807
Amphetamines negative	27.75	25.35	4	12479	0	34944448
Initial insomnia	27.74	25.35	16	12467	3108	34941340
Unevaluable event	27.54	25.35	45	12438	32545	34911903
Poor quality sleep	27.21	25.35	23	12460	8233	34936215
Product prescribing error	27.03	25.35	37	12446	22890	34921558
Palpitations	26.99	25.35	50	12433	39936	34904512
Off label use	26.70	25.35	247	12236	419277	34525171
Atrial fibrillation	25.85	25.35	6	12477	122387	34822061
General physical health deterioration	25.72	25.35	7	12476	128262	34816186

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Intentional self-injury	973.70	18.14	359	21930	32060	79690039
Product quality issue	924.93	18.14	350	21939	33590	79688509
Intentional overdose	681.84	18.14	403	21886	105557	79616542
Disturbance in attention	411.86	18.14	225	22064	50576	79671523
Tic	318.27	18.14	87	22202	2899	79719200
Product physical issue	293.55	18.14	88	22201	4097	79718002
Aggression	291.47	18.14	180	22109	50778	79671321
Suicidal ideation	258.46	18.14	195	22094	76145	79645954
Irritability	229.32	18.14	143	22146	41001	79681098
Psychomotor hyperactivity	207.42	18.14	99	22190	16750	79705349
Therapeutic product effect increased	201.55	18.14	53	22236	1518	79720581
Abnormal behaviour	179.12	18.14	117	22172	36304	79685795
Inappropriate schedule of product administration	176.93	18.14	202	22087	133426	79588673
Anxiety	165.57	18.14	269	22020	248243	79473856
Feeling abnormal	164.10	18.14	212	22077	158987	79563112
Wrong technique in product usage process	162.54	18.14	147	22142	73728	79648371
Drug ineffective	148.99	18.14	645	21644	1080268	78641831
Insomnia	148.07	18.14	254	22035	244916	79477183
Anger	130.64	18.14	73	22216	17089	79705010
Crying	128.11	18.14	80	22209	22963	79699136
Logorrhoea	125.88	18.14	47	22242	4318	79717781
Agitation	120.66	18.14	144	22145	99571	79622528
Choreoathetosis	118.73	18.14	35	22254	1535	79720564
No adverse event	116.97	18.14	91	22198	37101	79684998
Oppositional defiant disorder	115.44	18.14	27	22262	470	79721629
Attention deficit hyperactivity disorder	115.42	18.14	41	22248	3268	79718831
Bruxism	111.19	18.14	42	22247	3984	79718115
Acute kidney injury	108.83	18.14	10	22279	519394	79202705
Mood altered	104.38	18.14	64	22225	17783	79704316
Product tampering	103.37	18.14	24	22265	404	79721695
Homicidal ideation	102.53	18.14	38	22251	3419	79718680
Educational problem	98.85	18.14	23	22266	391	79721708
Product dose omission issue	98.44	18.14	215	22074	247322	79474777
Therapeutic product effect variable	97.95	18.14	32	22257	1977	79720122
Paranoia	96.92	18.14	63	22226	19369	79702730
Decreased eye contact	95.88	18.14	26	22263	839	79721260
Pneumonia	93.54	18.14	34	22255	660212	79061887
Dyskinesia	92.40	18.14	86	22203	44687	79677412
Therapeutic product effect decreased	91.31	18.14	164	22125	163699	79558400
Impulsive behaviour	90.15	18.14	33	22256	2867	79719232
Withdrawal syndrome	87.25	18.14	67	22222	26787	79695312
Mood swings	78.99	18.14	56	22233	19824	79702275
Negativism	77.54	18.14	22	22267	841	79721258
Disturbance in social behaviour	76.13	18.14	34	22255	4936	79717163
Anaemia	75.84	18.14	16	22273	444999	79277100
Dystonia	75.30	18.14	56	22233	21343	79700756
Depression	72.56	18.14	176	22113	216614	79505485
Incorrect dose administered	71.06	18.14	97	22192	76533	79645566
Feeling jittery	67.41	18.14	43	22246	12798	79709301
Depressed mood	66.97	18.14	75	22214	48405	79673694
Speech disorder	63.15	18.14	77	22212	54368	79667731
Affect lability	62.34	18.14	39	22250	11220	79710879
Neutropenia	58.97	18.14	6	22283	287704	79434395
Dermatitis atopic	58.64	18.14	36	22253	10020	79712079
Adulterated product	58.02	18.14	14	22275	280	79721819
Trismus	57.90	18.14	29	22260	5438	79716661
Death	55.77	18.14	46	22243	566468	79155631
Decreased appetite	53.42	18.14	213	22076	342205	79379894
Trichotillomania	53.10	18.14	12	22277	178	79721921
Claustrophobia	53.03	18.14	18	22271	1252	79720847
Therapeutic response unexpected	52.51	18.14	44	22245	19902	79702197
Product administered to patient of inappropriate age	51.69	18.14	27	22262	5526	79716573
Mania	51.66	18.14	42	22247	18218	79703881
Dermatillomania	51.35	18.14	12	22277	208	79721891
Prescribed overdose	51.28	18.14	58	22231	37825	79684274
Tardive dyskinesia	49.61	18.14	33	22256	10538	79711561
Pyrexia	49.24	18.14	71	22218	678638	79043461
Somnolence	48.52	18.14	162	22127	238819	79483280
Euphoric mood	48.50	18.14	29	22260	7697	79714402
Thrombocytopenia	48.43	18.14	8	22281	265251	79456848
Pulse abnormal	48.18	18.14	22	22267	3362	79718737
Therapeutic response shortened	48.10	18.14	38	22251	15825	79706274
Vision blurred	47.84	18.14	97	22192	105801	79616298
Heart rate increased	46.92	18.14	104	22185	120620	79601479
Nervousness	46.66	18.14	52	22237	33363	79688736
Sleep disorder	45.45	18.14	84	22205	85593	79636506
Hyperhidrosis	44.38	18.14	117	22172	151375	79570724
Tachyphrenia	44.38	18.14	18	22271	2062	79720037
Somatic symptom disorder	44.19	18.14	19	22270	2518	79719581
Palpitations	43.61	18.14	104	22185	126506	79595593
Psychotic disorder	40.79	18.14	54	22235	41348	79680751
Emotional disorder	40.50	18.14	33	22256	14354	79707745
Neurological symptom	40.21	18.14	27	22262	8756	79713343
General physical health deterioration	39.17	18.14	14	22275	275224	79446875
Joint swelling	38.89	18.14	16	22273	288630	79433469
Sepsis	37.84	18.14	14	22275	269414	79452685
Change in sustained attention	37.22	18.14	6	22283	10	79722089
Off label use	36.85	18.14	401	21888	906814	78815285
Diarrhoea	36.76	18.14	125	22164	880364	78841735
Febrile neutropenia	35.98	18.14	10	22279	230989	79491110
Serotonin syndrome	35.82	18.14	53	22236	44974	79677125
Hunger	35.71	18.14	21	22268	5407	79716692
Atrial fibrillation	33.89	18.14	7	22282	197879	79524220
Adrenergic syndrome	33.79	18.14	8	22281	147	79721952
Product administration interrupted	33.58	18.14	18	22271	3881	79718218
Coordination abnormal	33.31	18.14	32	22257	17280	79704819
Inability to afford medication	33.22	18.14	16	22273	2757	79719342
Total cholesterol/HDL ratio abnormal	32.83	18.14	7	22282	78	79722021
Headache	32.78	18.14	302	21987	653470	79068629
Accidental exposure to product by child	32.40	18.14	16	22273	2910	79719189
Oculogyric crisis	32.27	18.14	16	22273	2936	79719163
Haemoglobin decreased	32.11	18.14	11	22278	222108	79499991
Autism spectrum disorder	31.74	18.14	12	22277	1140	79720959
Pulmonary embolism	31.71	18.14	5	22284	171649	79550450
Platelet count decreased	31.12	18.14	8	22281	194656	79527443
Renal failure	30.74	18.14	9	22280	200959	79521140
Product availability issue	30.60	18.14	17	22272	3930	79718169
Contraindicated product administered	30.47	18.14	4	22285	157534	79564565
Hyperkinesia	30.45	18.14	15	22274	2714	79719385
Unevaluable event	30.10	18.14	55	22234	55530	79666569
Hyperreflexia	29.62	18.14	22	22267	8363	79713736
Insurance issue	29.60	18.14	19	22270	5714	79716385
Suicide attempt	29.49	18.14	69	22220	82863	79639236
Acne	29.18	18.14	37	22252	27153	79694946
Amenorrhoea	29.02	18.14	21	22268	7671	79714428
Obsessive-compulsive disorder	29.02	18.14	19	22270	5908	79716191
Rheumatoid arthritis	28.98	18.14	11	22278	208459	79513640
Initial insomnia	28.62	18.14	20	22269	6918	79715181
Thinking abnormal	28.54	18.14	26	22263	13135	79708964
Oedema peripheral	28	18.14	18	22271	252270	79469829
Screaming	27.95	18.14	16	22273	3917	79718182
Respiratory failure	27.86	18.14	8	22281	180903	79541196
Illness	27.73	18.14	48	22241	46463	79675636
Social avoidant behaviour	27.47	18.14	17	22272	4797	79717302
Brain injury	27.44	18.14	24	22265	11493	79710606
Malignant neoplasm progression	27.42	18.14	3	22286	135987	79586112
Drug diversion	27.30	18.14	11	22278	1239	79720860
Rabbit syndrome	27.04	18.14	8	22281	355	79721744
Cardiac failure congestive	26.64	18.14	4	22285	142398	79579701
Restlessness	26.44	18.14	47	22242	46445	79675654
Polydipsia psychogenic	26.40	18.14	7	22282	207	79721892
Tachycardia	26.40	18.14	109	22180	177659	79544440
Infusion related reaction	26.14	18.14	16	22273	230221	79491878
Memory impairment	25.60	18.14	79	22210	111655	79610444
Cardiac failure	25.46	18.14	6	22283	154836	79567263
Arthralgia	25.31	18.14	79	22210	571724	79150375
Arthropathy	25.20	18.14	9	22280	177102	79544997
Hypoaesthesia	25.10	18.14	108	22181	179244	79542855
Dissociation	25.00	18.14	15	22274	4006	79718093
Hallucination	24.87	18.14	66	22223	85679	79636420
Hypotension	24.70	18.14	54	22235	440263	79281836
Increased appetite	24.68	18.14	23	22266	11955	79710144
Dyspnoea	24.58	18.14	140	22149	856885	78865214
Panic attack	24.49	18.14	32	22257	24184	79697915
Renal impairment	24.25	18.14	7	22282	157776	79564323
Tremor	24.25	18.14	103	22186	169980	79552119
Stress cardiomyopathy	24.09	18.14	22	22267	11144	79710955
Drug intolerance	24.06	18.14	23	22266	264096	79458003
Mydriasis	23.85	18.14	27	22262	17616	79704483
Urinary tract infection	23.75	18.14	25	22264	274487	79447612
Gastrointestinal haemorrhage	23.74	18.14	6	22283	147713	79574386
Treatment failure	23.69	18.14	9	22280	170477	79551622
Systemic lupus erythematosus	23.61	18.14	3	22286	121146	79600953
Myocardial infarction	23.53	18.14	11	22278	184118	79537981
Exposure via skin contact	23.42	18.14	7	22282	322	79721777
Amphetamines positive	23.15	18.14	7	22282	335	79721764
Saccadic eye movement	22.94	18.14	6	22283	168	79721931
Streptococcal infection	22.25	18.14	19	22270	8811	79713288
Mobility decreased	21.59	18.14	4	22285	122171	79599928
Amphetamines negative	21.55	18.14	3	22286	0	79722099
Device expulsion	21.38	18.14	31	22258	25830	79696269
Sympathomimetic effect	20.77	18.14	5	22284	99	79722000
Feeling hot	20.48	18.14	49	22240	59685	79662414
Neuropathy peripheral	20.41	18.14	7	22282	141298	79580801
Drug dependence	20.40	18.14	39	22250	40730	79681369
Personality change	19.94	18.14	19	22270	10151	79711948
Fall	19.75	18.14	70	22219	487559	79234540
Hyponatraemia	19.30	18.14	13	22276	177835	79544264
Affective disorder	19.15	18.14	17	22272	8302	79713797
Hypertensive emergency	18.91	18.14	11	22278	2774	79719325
Stress	18.89	18.14	57	22232	79555	79642544
Infection	18.76	18.14	24	22265	241688	79480411
Peripheral swelling	18.71	18.14	29	22260	269588	79452511
Muscle spasms	18.45	18.14	97	22192	174633	79547466
Pre-existing condition improved	18.33	18.14	14	22275	5549	79716550

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N06BA12	NERVOUS SYSTEM PSYCHOANALEPTICS PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS Centrally acting sympathomimetics
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D000697	Central Nervous System Stimulants
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018765	Dopamine Uptake Inhibitors
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
FDA PE	N0000175729	Central Nervous System Stimulation
FDA EPC	N0000175739	Central Nervous System Stimulant

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Attention deficit hyperactivity disorder	indication	406506008
Binge eating disorder	indication	439960005
Narcolepsy	off-label use	60380001	DOID:8986
Gilles de la Tourette's syndrome	contraindication	5158005	DOID:11119
Bipolar disorder	contraindication	13746004	DOID:3312
Myocardial infarction	contraindication	22298006	DOID:5844
Glaucoma	contraindication	23986001	DOID:1686
Feeling agitated	contraindication	24199005
Hyperthyroidism	contraindication	34486009	DOID:7998
Hypertensive disorder	contraindication	38341003	DOID:10763
Conduction disorder of the heart	contraindication	44808001
Chronic heart failure	contraindication	48447003
Aggressive behavior	contraindication	61372001
Substance abuse	contraindication	66214007
Psychotic disorder	contraindication	69322001
Arteriosclerotic vascular disease	contraindication	72092001
Cardiomyopathy	contraindication	85898001	DOID:0050700
Weight loss	contraindication	89362005
Structural disorder of heart	contraindication	128599005
Seizure disorder	contraindication	128613002
Motor tic disorder	contraindication	230337001
Cerebrovascular accident	contraindication	230690007
Mania	contraindication	231494001
Visual impairment	contraindication	397540003
Breastfeeding (mother)	contraindication	413712001
Disorder of coronary artery	contraindication	414024009
Myocardial infarction in recovery phase	contraindication	418044006
Hypertensive urgency	contraindication	443482000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	12.84	acidic
pKa2	10.65	Basic
pKa3	7.51	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
10MG	VYVANSE	TAKEDA PHARMS USA	N021977	Oct. 30, 2014	RX	CAPSULE	ORAL	7659253	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N021977	Oct. 30, 2014	RX	CAPSULE	ORAL	7659254	Feb. 24, 2023	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
10MG	VYVANSE	TAKEDA PHARMS USA	N021977	Oct. 30, 2014	RX	CAPSULE	ORAL	7662788	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N021977	Oct. 30, 2014	RX	CAPSULE	ORAL	7671030	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N021977	Oct. 30, 2014	RX	CAPSULE	ORAL	7671031	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N021977	Oct. 30, 2014	RX	CAPSULE	ORAL	7674774	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N021977	Oct. 30, 2014	RX	CAPSULE	ORAL	7678770	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N021977	Oct. 30, 2014	RX	CAPSULE	ORAL	7687467	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N021977	Oct. 30, 2014	RX	CAPSULE	ORAL	7713936	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N021977	Oct. 30, 2014	RX	CAPSULE	ORAL	7718619	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7105486	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7105486	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7659253	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7659254	Feb. 24, 2023	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
20MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7662788	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7671030	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7671031	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7674774	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7678770	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7678771	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7687467	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7713936	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7718619	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7723305	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7105486	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7659253	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7659254	Feb. 24, 2023	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
30MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7662788	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7671030	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7671031	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7674774	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7678770	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7678771	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7687467	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7713936	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7718619	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7723305	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7105486	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7659253	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7659254	Feb. 24, 2023	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
40MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7662788	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7671030	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7671031	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7674774	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7678770	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7678771	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7687467	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7713936	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7718619	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7723305	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7105486	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7659253	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7659254	Feb. 24, 2023	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
50MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7662788	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7671030	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7671031	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7674774	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7678770	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7678771	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7687467	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7713936	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7718619	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7723305	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7105486	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7105486	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7659253	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7659254	Feb. 24, 2023	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
60MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7662788	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7671030	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7671031	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7674774	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7678770	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7678771	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7687467	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7713936	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7718619	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N021977	Dec. 10, 2007	RX	CAPSULE	ORAL	7723305	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
70MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7105486	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
70MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7659253	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
70MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7659254	Feb. 24, 2023	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
70MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7662788	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
70MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7671030	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
70MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7671031	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
70MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7674774	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
70MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7678770	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
70MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7678771	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
70MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7687467	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
70MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7713936	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
70MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7718619	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
70MG	VYVANSE	TAKEDA PHARMS USA	N021977	Feb. 23, 2007	RX	CAPSULE	ORAL	7723305	Feb. 24, 2023	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7105486	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7659253	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7659254	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7662788	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7671030	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7671031	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7674774	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7678770	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7678771	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7687467	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7713936	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7718619	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
10MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7723305	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7105486	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7659253	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7659254	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7662788	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7671030	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7671031	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7674774	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7678770	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7678771	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7687467	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7713936	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7718619	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
20MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7723305	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7105486	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7659253	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7659254	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7662788	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7671030	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7671031	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7674774	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7678770	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7678771	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7687467	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7713936	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7718619	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
30MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7723305	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7105486	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7659253	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7659254	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7662788	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7671030	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7671031	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7674774	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7678770	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7678771	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7687467	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7713936	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7718619	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
40MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7723305	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7105486	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7659253	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7659254	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7662788	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7671030	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7671031	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7674774	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7678770	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7678771	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7687467	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7713936	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7718619	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
50MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7723305	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7105486	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7659253	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7659254	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7662788	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7671030	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7671031	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7674774	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7678770	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7678771	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7687467	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7713936	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7718619	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
60MG	VYVANSE	TAKEDA PHARMS USA	N208510	Jan. 28, 2017	RX	TABLET, CHEWABLE	ORAL	7723305	Feb. 24, 2023	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN	RELEASING AGENT				CHEMBL	CHEMBL
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN	RELEASING AGENT				DRUGBANK	CHEMBL
Synaptic vesicular amine transporter	Transporter	Q05940	VMAT2_HUMAN	INHIBITOR				CHEMBL	CHEMBL

External reference:

ID	Source
4026030	VUID
N0000176089	NUI
D04747	KEGG_DRUG
608137-33-3	SECONDARY_CAS_RN
4026030	VANDF
4026031	VANDF
C1873633	UMLSCUI
CHEBI:135925	CHEBI
CHEMBL1201222	ChEMBL_ID
CHEMBL1201178	ChEMBL_ID
D000069478	MESH_DESCRIPTOR_UI
DB01255	DRUGBANK_ID
7213	IUPHAR_LIGAND_ID
8690	INN_ID
H645GUL8KJ	UNII
11597698	PUBCHEM_CID
673579	RXNORM
108098	MMSL
23471	MMSL
d06663	MMSL
011972	NDDF
011987	NDDF
425597005	SNOMEDCT_US
426249000	SNOMEDCT_US
427427002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Lisdexamfetamine Dimesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0370	CAPSULE	20 mg	ORAL	ANDA	28 sections
Lisdexamfetamine Dimesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0371	CAPSULE	30 mg	ORAL	ANDA	28 sections
Lisdexamfetamine Dimesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0372	CAPSULE	40 mg	ORAL	ANDA	28 sections
Lisdexamfetamine Dimesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0373	CAPSULE	50 mg	ORAL	ANDA	28 sections
Lisdexamfetamine Dimesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0374	CAPSULE	60 mg	ORAL	ANDA	28 sections
Lisdexamfetamine Dimesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0375	CAPSULE	70 mg	ORAL	ANDA	28 sections
Lisdexamfetamine Dimesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-6854	CAPSULE	10 mg	ORAL	ANDA	33 sections
Lisdexamfetamine Dimesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-6855	CAPSULE	20 mg	ORAL	ANDA	33 sections
Lisdexamfetamine Dimesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-6856	CAPSULE	30 mg	ORAL	ANDA	33 sections
Lisdexamfetamine Dimesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-6857	CAPSULE	40 mg	ORAL	ANDA	33 sections
Lisdexamfetamine Dimesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-6858	CAPSULE	50 mg	ORAL	ANDA	33 sections
Lisdexamfetamine Dimesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-6859	CAPSULE	60 mg	ORAL	ANDA	33 sections
Lisdexamfetamine Dimesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-6860	CAPSULE	70 mg	ORAL	ANDA	33 sections
Lisdexamfetamine Dimesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0406-5111	CAPSULE	10 mg	ORAL	ANDA	37 sections
Lisdexamfetamine Dimesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0406-5112	CAPSULE	20 mg	ORAL	ANDA	37 sections
Lisdexamfetamine Dimesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0406-5113	CAPSULE	30 mg	ORAL	ANDA	37 sections
Lisdexamfetamine Dimesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0406-5114	CAPSULE	40 mg	ORAL	ANDA	37 sections
Lisdexamfetamine Dimesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0406-5115	CAPSULE	50 mg	ORAL	ANDA	37 sections
Lisdexamfetamine Dimesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0406-5116	CAPSULE	60 mg	ORAL	ANDA	37 sections
Lisdexamfetamine Dimesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0406-5117	CAPSULE	70 mg	ORAL	ANDA	37 sections
Lisdexamfetamine Dimesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0527-4661	CAPSULE	10 mg	ORAL	ANDA	34 sections
Lisdexamfetamine Dimesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0527-4662	CAPSULE	20 mg	ORAL	ANDA	34 sections
Lisdexamfetamine Dimesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0527-4663	CAPSULE	30 mg	ORAL	ANDA	34 sections
Lisdexamfetamine Dimesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0527-4664	CAPSULE	40 mg	ORAL	ANDA	34 sections
Lisdexamfetamine Dimesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0527-4665	CAPSULE	50 mg	ORAL	ANDA	34 sections
Lisdexamfetamine Dimesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0527-4666	CAPSULE	60 mg	ORAL	ANDA	34 sections
Lisdexamfetamine Dimesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0527-4667	CAPSULE	70 mg	ORAL	ANDA	34 sections
LISDEXAMFETAMINE DIMESYLATE	HUMAN PRESCRIPTION DRUG LABEL	1	43602-306	CAPSULE	10 mg	ORAL	ANDA	21 sections
LISDEXAMFETAMINE DIMESYLATE	HUMAN PRESCRIPTION DRUG LABEL	1	43602-307	CAPSULE	20 mg	ORAL	ANDA	21 sections
LISDEXAMFETAMINE DIMESYLATE	HUMAN PRESCRIPTION DRUG LABEL	1	43602-308	CAPSULE	30 mg	ORAL	ANDA	21 sections